Cancers, Vol. 11, Pages 1154: Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer

Cancers, Vol. 11, Pages 1154: Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer Cancers doi: 10.3390/cancers11081154 Authors: Yea Eun Kang Jung Tae Kim Mi Ae Lim Chan Oh Lihua Liu Seung-Nam Jung Ho-Ryun Won Kyungmin Lee Jae Won Chang Hyon-Seung Yi Hyun Jin Kim Bon Jeong Ku Minho Shong Bon Seok Koo Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchyma...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research